A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

NCT06633354 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Safety and Efficacy Evaluation of Next-generation CD19-UCART

NCT05381181 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

NCT03796390 ·Status: UNKNOWN ·Phase: PHASE1

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

NCT06633341 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

NCT05907603 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

NCT05225831 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

NCT03614858 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma

NCT06491225 ·Status: TERMINATED ·Phase: PHASE1

A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer

NCT07333573 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT04166838 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

NCT04714593 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

NCT05902845 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

NCT04859569 ·Status: UNKNOWN ·Phase: PHASE3

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

NCT04691713 ·Status: UNKNOWN ·Phase: NA

CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

NCT04004637 ·Status: UNKNOWN ·Phase: PHASE1

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

NCT03638206 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

NCT05472857 ·Status: RECRUITING ·Phase: PHASE1

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

NCT04785833 ·Status: UNKNOWN ·Phase: NA

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

NCT05117138 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

NCT04008394 ·Status: UNKNOWN ·Phase: PHASE1

A Study of RD14-01 in Patients With Advanced Solid Tumors

NCT05638828 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

NCT03275493 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

NCT04572308 ·Status: COMPLETED ·Phase: PHASE1

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

NCT05017883 ·Status: RECRUITING ·Phase: NA